Early Asset Valuation Specialist

About AQEMIA

AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline.

Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology.

Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data.

We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization.

We are looking for an Early Asset Valuation Specialist to evaluate and value our potential drug candidates and internal pipeline assets. You will report directly to Théa, our Head of Finance, who has a strong background in financial modeling and corporate finance (ex-Morgan Stanley).

The Early Asset Valuation Specialist will provide competitive intelligence lead for internal assets and synthesize data into actionable insights. This role is key to present valuation findings and recommendations to Leadership and Board.

This role involves rigorous financial modeling, market analysis and strategic assessment to determine the value of pre-clinical pharmaceutical assets in development.

The position requires close collaboration with other stakeholders at AQEMIA: Leadership, Portfolio team or Program leaders to provide comprehensive valuations and contribute to strategic decision-making.

You will play a pivotal role in building our portfolio strategy and risk profile analysis which is the core business of AQEMIA.

Your RoleDevelop complex valuation models to assess the value of our potential drug candidates (using NPV, transactional comparables and other valuation methodologies) to inform go/no-go decision for our portfolio.Identify and evaluate potential risks associated with drug development, regulatory approval, and market entry.Analyse clinical trial data, regulatory pathways and market potential to inform valuation models.Conduct thorough market research to understand the competitive landscape, pricing strategies and potential market share.Monitor industry trends, competitor activities and market dynamics to provide strategic insights.Assess the strategic fit of potential assets within the company’s portfolio and AQEMIA’s overall strategy.Your Profile5+ years of experience in financial modeling, early asset valuation and analysis within either banking, consulting, VC, pharma or biotech companiesMaster’s Degree in Life Sciences, Finance and/or BusinessStrong understanding of the pharma and drug development process, regulatory environment and market dynamicsBusiness-oriented profile and attention to detail requiredStrong communication skills with the ability to synthesize data and complex information, and present succinctly to executives and stakeholders at all levelsHighly organised, flexible and easily adaptive to changing conditionsComfortable working in a fast paced and evolving environmentCurious and eager to learn more about finance, drug discovery and AIFluent in EnglishPreferred MindsetYou are driven to actively contribute to Aqemia’s mission of developing life-saving drugs for patientsYou bring a proactive and can-do attitude, solving complex problems with enthusiasm and a collaborative spiritYou thrive in a fast-paced and interdisciplinary environmentYou are motivated to leverage your skills and knowledge to make a tangible impact

Our recruitment process is the following :

1 - Qualification call: Nicolas, head of Talent Acquisition, and/or Théa

2 - Hiring Manager’s interview: you will meet with your future manager Théa in person

3 - Cultural fit interview with our co-founder and COO Emmanuelle

4 - Final interview with our co-founder and CEO Maximilien

Why Join Us ?

At AQEMIA, we work for a mission: joining us means having your own impact on changing the way drugs are discovered, and helping to shape the direction of our fast-growing company and team.

Expanding Drug Discovery Pipeline : Focused on critical diseases several types of cancers, with in vivo proof of concept/patent stage programs. Collaborations with top Pharma, including a $140M Sanofi deal.

Interdisciplinary Team : brilliant talent from tech and life sciences.

Experienced Leadership : Founders with 15+ years at ENS, Oxford, Cambridge, and BCG.

DeepTech Recognition: Part of French Tech 120 and France 2030.

Prime Location : Based in central Paris with the possibility of 2 remote days per week.

International Environment : The work language is English - relocation support and French lessons granted if needed.

Strong Financial Backing : $60M raised from leading European deeptech investors

---